Renaissance Capital logo

KLRA News

Obesity biotech Kailera Therapeutics prices upsized IPO at $16 high end

Kailera Therapeutics logo

Kailera Therapeutics, a phase 3 biotech developing injectable and oral GLP-1 agonists for obesity, raised $625 million by offering 39.1 million shares at $16, the high end of the $14 to $16 range. The company originally planned to offer 33.3 million shares at...read more

Obesity biotech Kailera Therapeutics sets terms for $500 million IPO

Kailera Therapeutics logo

Kailera Therapeutics, a Phase 3 biotech developing injectable and oral GLP-1s for obesity, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $500 million by offering 33.3 million shares at a price range of $14 to $16. Certain...read more

US IPO Week Ahead: 2 billion-dollar IPOs on the calendar, as ceasefire hopes entice more issuers

MAIR

Updated Monday, 4/13. Five sizable IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the week. Indoor air systems provider Madison Air Solutions (MAIR) is set to raise $2.2 billion at a $12.9 billion...read more

US Weekly Recap: Aerospace and healthcare issuers drive late-March filing activity

IPFXU

While there were no traditional IPOs this past week, three blank check companies priced, and several sizable deals joined the pipeline. The week’s three blank check IPOs were led by Inflection Point Acquisition VI (IPFXU), which raised $220 million to...read more